Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03582176
PHASE3

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

Sponsor: University of Calgary

View on ClinicalTrials.gov

Summary

PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.

Key Details

Gender

All

Age Range

18 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

395

Start Date

2019-04-26

Completion Date

2024-12-17

Last Updated

2026-07-27

Healthy Volunteers

No

Interventions

DRUG

Lactose Placebo

One capsule by mouth twice per day

DRUG

Ketotifen Fumarate 2mg

2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

DRUG

Ketotifen Fumarate 5mg

5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Locations (15)

University of Maryland Medical Centre

Baltimore, Maryland, United States

Carolinas Medical Center

Charlotte, North Carolina, United States

University of Vermont Medical Center

Burlington, Vermont, United States

Peter Lougheed Centre

Calgary, Alberta, Canada

Foothills Medical Centre

Calgary, Alberta, Canada

South Health Campus

Calgary, Alberta, Canada

Sturgeon Community Hospital

St. Albert, Alberta, Canada

Royal Columbia Hospital

New Westminster, British Columbia, Canada

St. Paul's Hospital

Vancouver, British Columbia, Canada

Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, Canada

St. Joseph's Health Care London

London, Ontario, Canada

The Ottawa General Hospital

Ottawa, Ontario, Canada

The Ottawa Civic Hospital

Ottawa, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

St. Michael's Hospital

Toronto, Ontario, Canada